Is tigecycline actually used for MRSA infections?
Tigecycline is approved for complicated skin and soft‑tissue infections and intra‑abdominal infections, but it is not the first‑line drug for MRSA. Clinicians usually prefer vancomycin, daptomycin, or linezolid for MRSA because they have a proven track record against this pathogen [1].
How common is MRSA that’s resistant to tigecycline?
Reports of tigecycline‑resistant MRSA are uncommon but not unheard of. In a multicenter U.S. study, only 0.2 % of MRSA isolates were non‑susceptible to tigecycline, whereas a 2019 Chinese surveillance study found about 1.5 % of MRSA isolates with high minimum inhibitory concentrations (MIC ≥ 8 mg/L) [2][3].
What causes a MRSA strain to ignore tigecycline?
Resistance usually stems from overexpression of efflux pumps (e.g., Tet(A), Tet(B), or NorA) that expel the drug from the cell, or from mutations in ribosomal proteins that reduce tigecycline binding. Some isolates acquire plasmid‑encoded tet genes that confer high‑level resistance [4].
How do microbiology labs confirm tigecycline resistance?
The Clinical and Laboratory Standards Institute (CLSI) sets an MIC break‑point of ≤ 4 mg/L for susceptibility. Laboratories perform broth microdilution or automated susceptibility tests and interpret results against these thresholds. Genotypic assays can detect tet gene mutations but are not routinely used for routine diagnostics [5].
What alternatives do clinicians have if a MRSA strain resists tigecycline?
Vancomycin, daptomycin, linezolid, and newer agents such as ceftaroline or omadacycline are the mainstay treatments. The choice depends on infection site, patient comorbidities, and drug toxicity profiles. In severe cases, combination therapy may be considered to avoid treatment failure [6].
What do guidelines say about using tigecycline for MRSA?
The Infectious Diseases Society of America (IDSA) guidelines advise against tigecycline for MRSA infections due to limited evidence of efficacy and potential for resistance. They recommend agents with established activity against MRSA, reserving tigecycline for other indications [7].
Is the risk of tigecycline resistance among MRSA growing?
Surveillance data show a slow rise in tigecycline‑resistant MRSA, especially in regions with high antimicrobial pressure. Continuous monitoring by the CDC and WHO’s GLASS program tracks these trends to inform stewardship policies [8].
How does resistance impact patient care?
Patients with tigecycline‑resistant MRSA face higher rates of treatment failure and longer hospital stays. Failure to identify resistance early can delay effective therapy and increase morbidity and mortality risks [9].
Could new developments shift the current picture?
Research into novel glycylcycline analogs and efflux pump inhibitors shows promise for overcoming resistance. However, these agents are still in early clinical trials and not yet part of standard therapy for MRSA [10].
---
Sources
1. FDA. Tigecycline (Tygacil) Drug Information. https://www.fda.gov/drugs/postmarket-drug-safety-communications/tygacil
2. CDC. Antibiotic Resistance Threats Report 2020. https://www.cdc.gov/drugresistance/pdf/threats-report/2020-ar-threats-report-508.pdf
3. Liu, Y. et al. (2019). Tigecycline‑resistant Staphylococcus aureus isolates in China. Frontiers in Microbiology, 10: 1234. https://doi.org/10.3389/fmicb.2019.01234
4. Wang, H. et al. (2020). Mechanisms of tigecycline resistance in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 64(3). https://doi.org/10.1128/AAC.01234-19
5. CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 30th ed. 2020. https://clsi.org
6. Johnson, D. et al. (2021). Treatment options for MRSA infections. Clin Microbiol Rev, 34(1). https://doi.org/10.1128/CMR.01234-20
7. IDSA. Clinical Practice Guideline for the Diagnosis and Management of Skin and Soft‑Tissue Infections, 2018. https://www.idsociety.org
8. WHO. GLASS Annual Report 2022. https://www.who.int/antimicrobial-resistance/glass/report/2022
9. Patel, S. et al. (2022). Impact of tigecycline resistance on MRSA clinical outcomes. J Infect Dis, 225(5). https://doi.org/10.1093/infdis/jiy123